Fig. 3From: Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resectionKaplan–Meier survival curves of patients with various baseline HBV levels and use of nucleotide/nucleoside analogs (NAs). a OS rates between the antiviral and non-antiviral groups. b DFS rates between the antiviral and non-antiviral groups. c OS rates between patients with baseline serum HBV DNA levels of ≥2000 and <2000 IU/mL or undetectable. d DFS rates between patients with baseline serum HBV DNA levels of ≥2000 and <2000 IU/mL or undetectableBack to article page